公衆衛生87巻2号

2023年02月発行

特集 シリーズ 公衆衛生と感染症—感染症に対する医薬品開発と医療の最前線

HIVに対する医薬品の開発と実用化の最前線

著者： 山本浩之¹

所属機関： ¹国立感染症研究所エイズ研究センター 第二研究グループ

ページ範囲：P.108 - P.115

ポイント
◆HIV感染の各ステップを標的とした多剤併用療法（cART）は有効であり、新薬開発とレジメン改良が常時進んでいる。
◆曝露前予防内服（PrEP）のHIV予防効果は高く、それをさらに容易にする長時間作用型治療薬も近年上市された。
◆HIVのウイルス学的・免疫学的理解の進展を踏まえた、他のウイルスに対するものと異なる制御法も探求されている。

参考文献

1）UNAIDS: Global HIV ＆ AIDS statistics — Fact sheet.　https://www.unaids.org/en/resources/fact-sheet（2022年9月14日閲覧）

2）Mattapallil JJ, et al: Massive infection and loss of memory CD4＋ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097, 2005

3）Tomaras GD, et al: Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M（IgM）and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82: 12449-12463, 2008

4）Mitsuya H, et al: 3'-Azido-3'-deoxythymidine（BW A509U）: an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type Ⅲ/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 82: 7096-7100, 1985

5）Hammer S M, et al: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 335: 1081-1090, 1996

6）Markowitz M, et al: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333: 1534-1539, 1995

7）HIV感染症および血友病におけるチーム医療の構築と医療水準の向上を目指した研究班：抗HIV治療ガイドライン2022年3月．　https://hiv-guidelines.jp/pdf/guideline2022.pdf（2022年9月14日閲覧）

8）Abdool Karim Q, et al: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174, 2010

9）McCormack S, et al: Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection（PROUD）: effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387: 53-60, 2016

10）Klatt NR, et al: Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 356: 938-945, 2017

11）Baert L, et al: Development of a long-acting injectable formulation with nanoparticles of rilpivirine（TMC278）for HIV treatment. Eur J Pharm Biopharm 72: 502-508, 2009

12）Landovitz RJ, et al: Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 385: 595-608, 2021

13）Overton ET, et al: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection（ATLAS-2M）, 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet 396: 1994-2005, 2001

14）Delany-Moretlwe S, et al: Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399: 1779-1789, 2022

15）WHO: WHO recommends long-acting cabotegravir for HIV prevention.　https://www.who.int/news/item/28-07-2022-who-recommends-long-acting-cabotegravir-for-hiv-prevention（2022年9月14日閲覧）

16）Barouch DH, et al: Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503: 224-228, 2013

17）Matsushita S, et al: Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS 29: 453-462, 2015

18）Iseda S, et al: Biphasic CD8＋ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization. J Virol 90: 6276-6290, 2016

19）Julg B, et al: Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med 28: 1288-1296, 2022

20）Casazza JP, et al: Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med 28: 1022-1030, 2022

21）Laird GM, et al: Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125: 1901-1912, 2015

22）Halper-Stromberg A, et al: Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158: 989-999, 2014

23）Whitney JB, et al: Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512: 74-77, 2014

24）Sáez-Cirión A, et al: Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9: e1003211, 2013

25）Cele S, et al: SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe 30: 154-162. e5, 2022